Milrinone
As of the edition of 20 October 2026, Milrinone is a small molecule: marketed, first approved in 1987 (FR); acts on PDE3A.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2019
- Kind
- Small molecule
- Brand name
- Primacor
- First approved
- 16 October 1987 (FR)
- Approvals on record
- 8 in 4 regions
- Holder of the most recent approval
- Sanofi; 2 holders in all
- Registered trials
- 24, 2 stopped early
- Disease areas
- Heart and blood vessels; Lungs and airways; Inherited and neonatal; Pregnancy and women's health; Urinary and reproductive; Injuries
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PDE3A | cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A | Q14432 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 9 | 6 | 0 | 1 |
| Phase 1 | 2 | 2 | 0 | 0 |
| Phase 2 | 8 | 5 | 1 | 1 |
| Phase 3 | 5 | 4 | 0 | 0 |
| All trials | 24 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Sanofi | Applicant | 1987 to now |